太龙药业拟不超4.5亿定增江西国资委入主 复牌跌4.4%

Core Viewpoint - Tai Long Pharmaceutical (600222.SH) has resumed trading after a significant shareholder change, with shares closing at 8.20 yuan, down 4.43%, and a total market capitalization of 4.706 billion yuan [1] Group 1: Shareholder Change and Stock Resumption - The company announced that its controlling shareholder, Tai Rong Chan Investment, is planning a share transfer that may lead to a change in control [1] - The stock was suspended from trading on December 2, 2025, and initially expected to resume on December 4, but continued to be suspended until December 9, 2025 [1] - The resumption of trading occurred after an agreement was reached regarding the share transfer [1] Group 2: A-Share Issuance - The company plans to issue A-shares to specific investors, aiming to raise up to 454.35 million yuan, which will be used for working capital and repaying interest-bearing debts [2] - The shares will be issued at a price of 6.09 yuan per share, which is not less than 80% of the average trading price over the previous 20 trading days [3] - The issuance will involve a maximum of 74,605,216 shares, representing 13% of the total share capital before the issuance [3] Group 3: Share Transfer Agreement - On December 8, 2025, Jiang Pharmaceutical Holdings signed a share transfer agreement with Tai Rong Chan Investment to acquire 50,100,000 shares, which is 8.73% of the total share capital before the issuance [4] - The share transfer will occur in two tranches, with the first tranche involving 42,300,000 shares and the second tranche involving 7,800,000 shares [4] - An action agreement was also signed, ensuring that Tai Rong Chan Investment and Jiang Pharmaceutical Holdings will act in concert regarding major decisions affecting the company [4] Group 4: Control Changes - Following the completion of the first share transfer and the action agreement, Jiang Pharmaceutical Holdings will become the controlling shareholder, with the actual controller being the Jiangxi Provincial State-owned Assets Supervision and Administration Commission [5] - Jiang Pharmaceutical Holdings will hold 42,300,000 shares, while Tai Rong Chan Investment will retain 40,141,168 shares, giving them a combined control of 82,441,168 shares, or 14.37% of the total share capital [6] - The issuance of A-shares to Jiang Pharmaceutical Holdings will not change the control of the company, as they will remain the controlling shareholder [6]